Six novel target compounds 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione (ADT) based fibrates were synthesized and evaluated. All the synthesized compounds were preliminarily screened by using the Triton WR-1339-induecd hyperlipidemia model, in which T1 exhibited more potent hypolipidemic property than positive drug fenofibrate (FF). T1 also significantly decreased serum triglycerides (TG), total cholesterol (TC) and low density lipoprotein cholesterin (LDL) in methionine solution (Mets) induced hyperlipidemic mice. Moreover, hepatic transaminases (AST and ALT) were obviously ameliorated after treatment with T1 and the histological observation indicated that T1 ameliorated the injury in liver tissue and inhibited the hepatic lipid accumulation. In the livers of T1-administrated rat, the levels of PPARα related to lipids metabolism were up-regulated. Additional effects such as antioxidant, anti-inflammatory and H₂S releasing action confirmed and reinforced the activity of T1 as a potential multifunctional hypolipidemic and hepatoprotective agent.

合成并评估了六种新型目标化合物5-（4-羟苯基）-3H-1,2-二硫基-3-硫酮（ADT）。使用Triton WR-1339-induecd高脂血症模型初步筛选了所有合成的化合物，其中T1表现出比阳性药物非诺贝特（FF）更强的降血脂特性。T1还显着降低了蛋氨酸溶液（Mets）诱导的高脂血症小鼠的血清甘油三酸酯（TG），总胆固醇（TC）和低密度脂蛋白胆固醇（LDL）。此外，经T1处理后，肝转氨酶（AST和ALT）明显改善，并且组织学观察表明，T1改善了肝组织的损伤并抑制了肝脂质的积累。在施用T1的大鼠的肝脏中，与脂质代谢有关的PPARα水平上调。₂ S释放作用证实并增强了T1作为潜在的多功能降血脂和肝保护剂的活性。